Caproate

All Categories Medications / Interventions » Cc » Caproate

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

Condition: Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
Intervention: Drug: ASQ-3, Bayley III, Neurologic exam
Sponsors: KV Pharmaceutical Company; KV Pharmaceutical Company; Registrat-Mapi
Recruiting - verified February 2012
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)

Condition: Preterm Delivery
Interventions: Drug: 17-alpha-hydroxy-progesterone caproate, Makena®; Drug: Castor Oil (Placebo)
Sponsors: Obstetrix Medical Group; Obstetrix Medical Group
Recruiting - verified March 2012
Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.

Condition: Pregnancy Complications
Intervention: Drug: 17-Hydroxyprogesterone Caproate vs Castor oil (placebo)
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery

Condition: Preterm Birth
Interventions: Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug: Vehicle
Sponsors: KV Pharmaceutical Company; KV Pharmaceutical Company; ResearchPoint Global
Recruiting - verified May 2012

Main Menu

Clinical Trial Categories

Clinical Trial Locations

Sponsors/Recruiting

Join Clinical Trials

Caproate Clinical Trials

Caproate

Caproate